More recently, we have identified HDAC7 as a prognostic factor and biomarker of survival in infants with pro-B acute lymphoblastic leukemia (pro-B-ALL) and MLL-AF4 rearrangement, who display a general loss in HDAC7 expression; notably, the lowest levels of HDAC7 are associated with the poorest outcome for the infants (27). Here, KMT2A is linked to acute lymphoblastic leukemia.